Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
HealthCentral CEO Justin Chase joins to discuss the drops app and its mission to combat medical misinformation and improve access to trusted health info.
Rob Thummel of Tortoise Capital breaks down oil prices, geopolitical risks, and what a volatile energy market could mean for investors and consumers this summer
Paul Dergarabedian, Head of Marketplace Trends for Comscore, joins to discuss Disney earnings, industry leadership shifts and the 2026 box office outlook today.
The new space race isn't about just astronauts, it's about data. Hawkeye 360 CEO John Serafini on satellites, national security, and the company's recent IPO.
